Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Current Deferred Revenue (2022 - 2025)

AVITA Medical filings provide 4 years of Current Deferred Revenue readings, the most recent being $323000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 9.52% to $323000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $323000.0, a 9.52% decrease, with the full-year FY2025 number at $323000.0, down 9.52% from a year prior.
  • Current Deferred Revenue hit $323000.0 in Q4 2025 for AVITA Medical, down from $331000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $698000.0 in Q4 2022 to a low of $205000.0 in Q2 2024.
  • Median Current Deferred Revenue over the past 4 years was $365000.0 (2024), compared with a mean of $414000.0.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 63.2% in 2024 and later surged 65.85% in 2025.
  • AVITA Medical's Current Deferred Revenue stood at $698000.0 in 2022, then tumbled by 44.13% to $390000.0 in 2023, then fell by 8.46% to $357000.0 in 2024, then decreased by 9.52% to $323000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $323000.0 (Q4 2025), $331000.0 (Q3 2025), and $340000.0 (Q2 2025) per Business Quant data.